Dear User, This website provides you with information only for healthcare professionals. According to the drug promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have full access to our website. To visit our page please login.

Daiichi Sankyo
Doc Check

European News

Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with Relapsed/Refractory B-Cell Lymphoma

Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D

HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated NSCLC

Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 with Sarah Cannon Research Institute

New Biomarker Analyses from Patritumab Deruxtecan Phase 1 Study in Patients with EGFR-Mutated NSCLC Presented at WCLC 2020

Datopotamab Deruxtecan and ENHERTU Show Promising Early Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer

ENHERTU® Receives Prime Minister’s Award from the Japan Techno-Economics Society

ENHERTU® Approved in the EU for the Treatment of HER2 Positive Metastatic Breast Cancer

New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo’s Continued Commitment in Lung Cancer

First-in-class cholesterol-lowering treatment NILEMDO® ▼ (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® ▼ (bempedoic acid and ezetimibe) tablet approved in Switzerland

Global News

Global LIXIANA® Press Portal

Cookie preferences tool